Biochemical and Biophysical Research Communications 377 (2008) 1331
Contents lists available at ScienceDirect
Biochemical and Biophysical Research Communications journal homepage: www.elsevier.com/locate/ybbrc
Corrigendum
Corrigendum to ‘‘Immunogenic gangliosides in human ovarian carcinoma” [Biochem. Biophys. Res. Commun. 353 (2007) 251–258] Mepur H. Ravindranath a,*, Sakunthala Muthugounder a, Naftali Presser a, Senthamil R. Selvan b, Alessandro D. Santin c, Stefania Bellone c, Thiruverkadu S. Saravanan a, Donald L. Morton a a
Laboratory of Glycoimmunotherapy, John Wayne Cancer Institute at Saint John’s Health Center, 2200 Santa Monica Boulevard, Santa Monica, CA 90404-2302, USA Cell Biology Laboratory, Hoag Cancer Center, Newport Beach, CA, USA c Department of Obstetrics and Gynecology, University of Arkansas for Medical Science, Little Rock, AR, USA b
The authors regret the inadvertent omission of the following note to Table 2: The clinical characteristics of patients were pooled and modified (with additional patient information, #21, C49) from our previous paper [Santin AD, Ravindranath MH, Bellone S, Muthugounder S, Palmieri M, O’Brien TJ, Roman J, Cannon MJ, Pecorelli S. Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG 2004 Jun;111(6):613–8].
DOI of original article: 10.1016/j.bbrc.2006.12.001 * Corresponding author. E-mail address:
[email protected] (M.H. Ravindranath). 0006-291X/$ - see front matter Ó 2008 Elsevier Inc. All rights reserved. doi:10.1016/j.bbrc.2008.09.103
